Directorate Change | 01-May-2024 | 11:10 | RNS |
Haleon 2024 Q1 Trading Statement | 01-May-2024 | 07:00 | RNS |
Appointment of Dawn Allen as CFO | 24-Apr-2024 | 07:00 | RNS |
Notice of Annual General Meeting (AGM) | 12-Apr-2024 | 12:00 | RNS |
Director/PDMR Shareholding | 03-Apr-2024 | 11:30 | RNS |
Total Voting Rights and Capital | 02-Apr-2024 | 09:15 | RNS |
Holding(s) in Company | 22-Mar-2024 | 11:30 | RNS |
Haleon | 21-Mar-2024 | 18:00 | RNS |
Total Voting Rights and Capital | 21-Mar-2024 | 16:38 | RNS |
Closing of Secondary Global Offering by Pfizer | 21-Mar-2024 | 16:05 | RNS |
Final prospectus supplement filed with the SEC | 20-Mar-2024 | 08:39 | RNS |
Pricing and upsize of Secondary Global Offering | 19-Mar-2024 | 07:00 | RNS |
Preliminary prospectus supplement filed with SEC | 18-Mar-2024 | 11:00 | RNS |
Proposed Secondary Global Offering by Pfizer Inc. | 18-Mar-2024 | 07:00 | RNS |
Publication of Annual Report and Form 20-F 2023 | 15-Mar-2024 | 15:00 | RNS |
Currency | UK Pounds |
Share Price | 329.90p |
Change Today | 1.30p |
% Change | 0.40 % |
52 Week High | 346.55 |
52 Week Low | 308.55 |
Volume | 31,717,296 |
Shares Issued | 9,132m |
Market Cap | £30,128m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Latest | Previous | |
---|---|---|
Final | Interim | |
Ex-Div | 14-Mar-24 | 24-Aug-23 |
Paid | 16-May-24 | 05-Oct-23 |
Amount | 4.20p | 1.80p |
Time | Volume / Share Price |
16:35 | 1,359,008 @ 329.46p |
16:35 | 766,824 @ 329.46p |
16:35 | 5,998,715 @ 329.90p |
16:35 | 947 @ 329.90p |
16:35 | 4,260 @ 329.90p |
CFO | Tobias Hestler |
CEO | Brian McNamara |
CEO | Deirdre Mahlan |
You are here: research